Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Assembly Biosciences management to meet virtually with Mizuho » 04:55
01/26/23
01/26
04:55
01/26/23
04:55
ASMB

Assembly Biosciences

$1.67 /

+0.12 (+7.77%)

Virtual Meetings to be…

Virtual Meetings to be held January 24-26 hosted by Mizuho.

ShowHide Related Items >><<
ASMB Assembly Biosciences
$1.67 /

+0.12 (+7.77%)

ASMB Assembly Biosciences
$1.67 /

+0.12 (+7.77%)

11/16/22 Mizuho
Assembly Biosciences price target lowered to $3 from $14 at Mizuho
10/24/22 Truist
Assembly Biosciences downgraded to Hold from Buy at Truist
07/21/22 H.C. Wainwright
Assembly price target lowered to $2.50 from $3.50 at H.C. Wainwright
04/01/22 Truist
Assembly Biosciences price target lowered to $12 from $15 at Truist
ASMB Assembly Biosciences
$1.67 /

+0.12 (+7.77%)

Conference/Events
Assembly Biosciences management to meet virtually with Mizuho » 05:55
01/25/23
01/25
05:55
01/25/23
05:55
ASMB

Assembly Biosciences

$1.55 /

+0.035 (+2.32%)

Virtual Meetings to be…

Virtual Meetings to be held January 24-26 hosted by Mizuho.

ShowHide Related Items >><<
ASMB Assembly Biosciences
$1.55 /

+0.035 (+2.32%)

ASMB Assembly Biosciences
$1.55 /

+0.035 (+2.32%)

11/16/22 Mizuho
Assembly Biosciences price target lowered to $3 from $14 at Mizuho
10/24/22 Truist
Assembly Biosciences downgraded to Hold from Buy at Truist
07/21/22 H.C. Wainwright
Assembly price target lowered to $2.50 from $3.50 at H.C. Wainwright
04/01/22 Truist
Assembly Biosciences price target lowered to $12 from $15 at Truist
ASMB Assembly Biosciences
$1.55 /

+0.035 (+2.32%)

Conference/Events
Assembly Biosciences management to meet virtually with Mizuho » 04:55
01/24/23
01/24
04:55
01/24/23
04:55
ASMB

Assembly Biosciences

$1.52 /

+0.01 (+0.66%)

Virtual Meetings to be…

Virtual Meetings to be held January 24-26 hosted by Mizuho.

ShowHide Related Items >><<
ASMB Assembly Biosciences
$1.52 /

+0.01 (+0.66%)

ASMB Assembly Biosciences
$1.52 /

+0.01 (+0.66%)

11/16/22 Mizuho
Assembly Biosciences price target lowered to $3 from $14 at Mizuho
10/24/22 Truist
Assembly Biosciences downgraded to Hold from Buy at Truist
07/21/22 H.C. Wainwright
Assembly price target lowered to $2.50 from $3.50 at H.C. Wainwright
04/01/22 Truist
Assembly Biosciences price target lowered to $12 from $15 at Truist
ASMB Assembly Biosciences
$1.52 /

+0.01 (+0.66%)

Conference/Events
Assembly Biosciences management to meet virtually with Mizuho » 08:06
01/20/23
01/20
08:06
01/20/23
08:06
ASMB

Assembly Biosciences

$1.51 /

-0.015 (-0.98%)

Virtual Meetings to be…

Virtual Meetings to be held January 24-26 hosted by Mizuho.

ShowHide Related Items >><<
ASMB Assembly Biosciences
$1.51 /

-0.015 (-0.98%)

ASMB Assembly Biosciences
$1.51 /

-0.015 (-0.98%)

11/16/22 Mizuho
Assembly Biosciences price target lowered to $3 from $14 at Mizuho
10/24/22 Truist
Assembly Biosciences downgraded to Hold from Buy at Truist
07/21/22 H.C. Wainwright
Assembly price target lowered to $2.50 from $3.50 at H.C. Wainwright
04/01/22 Truist
Assembly Biosciences price target lowered to $12 from $15 at Truist
ASMB Assembly Biosciences
$1.51 /

-0.015 (-0.98%)

Over a month ago
Hot Stocks
Assembly announces interim results from studies on ABI-H3733, ABI-4334 » 08:22
12/19/22
12/19
08:22
12/19/22
08:22
ASMB

Assembly Biosciences

$1.16 /

-0.01 (-0.85%)

Assembly Biosciences…

Assembly Biosciences announced promising interim efficacy, safety and pharmacokinetic results from two ongoing clinical studies of its investigational next-generation HBV core inhibitors, a Phase 1b clinical study of ABI-H3733 and a Phase 1a clinical study of ABI-4334. Phase 1b Study for 3733 - Study ABI-H3733-102: The ongoing Phase 1b clinical trial is a randomized, multi-center, double-blind and placebo-controlled study evaluating the safety, PK and antiviral activity of 3733. The dose selected for the first cohort was 50 mg. 50 mg Cohort Efficacy: As of the data cutoff date of December 18, 2022, dosing in the 3733 Phase 1b trial has been completed for all 10 patients in the first cohort of 50 mg. Nine of 10 patients enrolled were HBeAg negative, so efficacy data are provided for these patients. Interim efficacy results from this cohort at the data cutoff date include HBV DNA, HBV RNA and antigen measurements for all patients for the full 28-day dosing period. In the 50 mg cohort, six of eight patients receiving 3733 achieved HBV DNA less than the lower limit of quantification within 21 days, with a mean decline in HBV DNA over the treatment period of approximately 3.1 logs. Data on HBV RNA declines were limited due to low baseline levels in predominantly e-antigen negative patients. 25 mg Cohort Efficacy: The second cohort, evaluating a dose of 25 mg, is fully enrolled. Nine of 10 patients enrolled were HBeAg negative, so efficacy data are provided for these patients. In the five patients that have so far completed 28 days of treatment, the mean reduction in HBV DNA was approximately 1.9 logs. 50 and 25 mg Cohorts: Safety data reported here reflect data received for both cohorts through the data cutoff date. In these initial cohorts, all treatment-emergent adverse events and laboratory abnormalities reported were Grade 1 or Grade 2. Further, no AEs led to treatment discontinuation. The observed PK for the new tablet formulation of 3733 was consistent with predictions from preclinical studies, providing exposure equivalent to the liquid formulation evaluated in the Phase 1a study for 3733. As expected given the 28-day dosing period, limited changes in viral antigens were observed in both the 50 mg and 25 mg cohorts. Phase 1a Study for 4334 - Study ABI-4334-101: The Phase 1a clinical trial is a randomized, blinded and placebo-controlled study evaluating the safety, tolerability and PK of 4334 following single ascending dose and multiple ascending dose administration in healthy subjects. Dosing has completed for all eight subjects in the initial 30 mg single dose cohort. In this cohort, 4334 had a mean half-life of 24 hours, supporting once-a-day dosing. In this initial cohort, treatment-emergent AEs and laboratory abnormalities were mild to moderate and all were considered not related to study treatment. A dose of 100 mg has been selected for the second single-dose cohort. Dosing for the second cohort is complete and initial data from this cohort are anticipated in the first quarter of 2023.

ShowHide Related Items >><<
ASMB Assembly Biosciences
$1.16 /

-0.01 (-0.85%)

ASMB Assembly Biosciences
$1.16 /

-0.01 (-0.85%)

11/16/22 Mizuho
Assembly Biosciences price target lowered to $3 from $14 at Mizuho
10/24/22 Truist
Assembly Biosciences downgraded to Hold from Buy at Truist
07/21/22 H.C. Wainwright
Assembly price target lowered to $2.50 from $3.50 at H.C. Wainwright
04/01/22 Truist
Assembly Biosciences price target lowered to $12 from $15 at Truist
ASMB Assembly Biosciences
$1.16 /

-0.01 (-0.85%)

Recommendations
Assembly Biosciences price target lowered to $3 from $14 at Mizuho » 06:44
11/16/22
11/16
06:44
11/16/22
06:44
ASMB

Assembly Biosciences

$1.39 /

-0.05 (-3.47%)

Mizuho analyst Salim Syed…

Mizuho analyst Salim Syed lowered the firm's price target on Assembly Biosciences to $3 from $14 and keeps a Buy rating on the shares. The analyst updated his model post the Q3 results.

ShowHide Related Items >><<
ASMB Assembly Biosciences
$1.39 /

-0.05 (-3.47%)

ASMB Assembly Biosciences
$1.39 /

-0.05 (-3.47%)

10/24/22 Truist
Assembly Biosciences downgraded to Hold from Buy at Truist
07/21/22 H.C. Wainwright
Assembly price target lowered to $2.50 from $3.50 at H.C. Wainwright
04/01/22 Truist
Assembly Biosciences price target lowered to $12 from $15 at Truist
ASMB Assembly Biosciences
$1.39 /

-0.05 (-3.47%)

Hot Stocks
Assembly Biosciences begins dosing in Phase 1a trial of ABI-4334 » 08:21
11/14/22
11/14
08:21
11/14/22
08:21
ASMB

Assembly Biosciences

$1.35 /

+0.025 (+1.89%)

Assembly Biosciences…

Assembly Biosciences announced that the first subject has been dosed in the Phase 1a trial of its investigational core inhibitor ABI-4334. 4334 is an investigational next-generation core inhibitor that is optimized for significantly increased potency against covalently closed circular DNA formation and new virus production versus first-generation core inhibitors. In preclinical research, 4334 has demonstrated sub-nanomolar potency against pgRNA encapsidation and 2-3 nanomolar potency against cccDNA formation. The Phase 1a clinical trial is a randomized, blinded and placebo-controlled study that will evaluate the safety, tolerability and pharmacokinetics of 4334 following single ascending dose and multiple ascending dose administration in healthy participants. The objectives of the study include the proportion of subjects with adverse events, premature treatment discontinuation due to AEs and abnormal laboratory results. Results of the trial will support dose selection for a future Phase 2 trial.

ShowHide Related Items >><<
ASMB Assembly Biosciences
$1.35 /

+0.025 (+1.89%)

ASMB Assembly Biosciences
$1.35 /

+0.025 (+1.89%)

10/24/22 Truist
Assembly Biosciences downgraded to Hold from Buy at Truist
07/21/22 H.C. Wainwright
Assembly price target lowered to $2.50 from $3.50 at H.C. Wainwright
04/01/22 Truist
Assembly Biosciences price target lowered to $12 from $15 at Truist
ASMB Assembly Biosciences
$1.35 /

+0.025 (+1.89%)

Conference/Events
American Association for Study of Liver Diseases to hold a meeting » 04:55
11/08/22
11/08
04:55
11/08/22
04:55
WXXWY

Wuxi Biologics

$12.05 /

+0.95 (+8.56%)

, VIR

Vir Biotechnology

$27.25 /

+1.56 (+6.07%)

, SRZN

Surrozen

$1.97 /

-0.03 (-1.50%)

, LGND

Ligand

$62.79 /

+0.91 (+1.47%)

, LLY

Eli Lilly

$365.17 /

+7.95 (+2.23%)

, EXEL

Exelixis

$16.37 /

-0.095 (-0.58%)

, EXAS

Exact Sciences

$38.13 /

+0.585 (+1.56%)

, BAYRY

Bayer

$13.71 /

+0.19 (+1.41%)

, BD

Budget Group

/

+

, BMRN

BioMarin

$81.28 /

-1.15 (-1.40%)

, BMY

Bristol-Myers

$79.21 /

+0.395 (+0.50%)

, CALT

Calliditas Therapeutics

$14.91 /

-0.555 (-3.59%)

, ALBO

Albireo Pharma

$22.36 /

+0.74 (+3.42%)

, ALGS

Aligos Therapeutics

/

+

, ALIM

Alimera Sciences

$5.50 /

+0.23 (+4.36%)

, ALNY

Alnylam

$204.94 /

-3.4 (-1.63%)

, ALT

Altimmune

$11.63 /

-0.18 (-1.52%)

, ALXN

Alexion

$182.40 /

+ (+0.00%)

, ASMB

Assembly Biosciences

$1.49 /

-0.04 (-2.61%)

, AXLA

Axcella Health

/

+

, JNJ

Johnson & Johnson

$173.05 /

+1.74 (+1.02%)

, KMDA

Kamada

$4.33 /

-0.05 (-1.14%)

, IPSEY

Ipsen

$25.84 /

+ (+0.00%)

, IVA

Inventiva

$4.23 /

-0.04 (-0.94%)

, SLP

Simulations Plus

$40.19 /

+2.3 (+6.07%)

, SMMNY

Siemens Healthineers

$23.01 /

+0.25 (+1.10%)

, SIEGY

Siemens

$57.53 /

+1.04 (+1.84%)

, RARE

Ultragenyx

$35.07 /

-0.255 (-0.72%)

, PKI

PerkinElmer

$128.99 /

-1.49 (-1.14%)

, NVO

Novo Nordisk

$115.09 /

+2.63 (+2.34%)

, GSK

GSK

$31.95 /

-1.055 (-3.20%)

, GLTO

Galecto

$2.04 /

-0.09 (-4.23%)

, GILD

Gilead

$81.47 /

+1.09 (+1.36%)

AASLD 2022: The Liver…

AASLD 2022: The Liver Meeting to be held in Washington, DC on November 4-8.

ShowHide Related Items >><<
VIR Vir Biotechnology
$27.25 /

+1.56 (+6.07%)

SRZN Surrozen
$1.97 /

-0.03 (-1.50%)

SMMNY Siemens Healthineers
$23.01 /

+0.25 (+1.10%)

SIEGY Siemens
$57.53 /

+1.04 (+1.84%)

RARE Ultragenyx
$35.07 /

-0.255 (-0.72%)

PKI PerkinElmer
$128.99 /

-1.49 (-1.14%)

NVO Novo Nordisk
$115.09 /

+2.63 (+2.34%)

LLY Eli Lilly
$365.17 /

+7.95 (+2.23%)

LGND Ligand
$62.79 /

+0.91 (+1.47%)

KMDA Kamada
$4.33 /

-0.05 (-1.14%)

JNJ Johnson & Johnson
$173.05 /

+1.74 (+1.02%)

IPSEY Ipsen
$25.84 /

+ (+0.00%)

GSK GSK
$31.95 /

-1.055 (-3.20%)

GLTO Galecto
$2.04 /

-0.09 (-4.23%)

GILD Gilead
$81.47 /

+1.09 (+1.36%)

EXEL Exelixis
$16.37 /

-0.095 (-0.58%)

EXAS Exact Sciences
$38.13 /

+0.585 (+1.56%)

CALT Calliditas Therapeutics
$14.91 /

-0.555 (-3.59%)

BMY Bristol-Myers
$79.21 /

+0.395 (+0.50%)

BMRN BioMarin
$81.28 /

-1.15 (-1.40%)

BAYRY Bayer
$13.71 /

+0.19 (+1.41%)

AXLA Axcella Health
/

+

ASMB Assembly Biosciences
$1.49 /

-0.04 (-2.61%)

ALXN Alexion
$182.40 /

+ (+0.00%)

ALT Altimmune
$11.63 /

-0.18 (-1.52%)

ALNY Alnylam
$204.94 /

-3.4 (-1.63%)

ALIM Alimera Sciences
$5.50 /

+0.23 (+4.36%)

ALGS Aligos Therapeutics
/

+

ALBO Albireo Pharma
$22.36 /

+0.74 (+3.42%)

WXXWY Wuxi Biologics
$12.05 /

+0.95 (+8.56%)

04/26/22 Bernstein
Wuxi Biologics initiated with an Outperform at Bernstein
VIR Vir Biotechnology
$27.25 /

+1.56 (+6.07%)

09/14/22 SVB Securities
SVB Securities bullish on Vir Biotechnology, initiates with an Outperform
09/14/22 SVB Securities
Vir Biotechnology initiated with an Outperform at SVB Securities
09/09/22 Morgan Stanley
Vir Biotechnology initiated with an Underweight at Morgan Stanley
05/12/22 H.C. Wainwright
Vir Biotechnology price target lowered to $125 from $250 at H.C. Wainwright
SRZN Surrozen
$1.97 /

-0.03 (-1.50%)

10/17/22 JPMorgan
Surrozen initiated with a Neutral at JPMorgan
05/27/22 BofA
Surrozen downgraded to Neutral from Buy at BofA
LGND Ligand
$62.79 /

+0.91 (+1.47%)

10/25/22 H.C. Wainwright
Ligand target lowered to $135 at H.C. Wainwright after OmniAb deal approved
10/25/22 Barclays
Ligand price target lowered to $150 from $157 at Barclays
09/02/22 Roth MKM
Ligand price target lowered to $175 from $185 at Roth Capital
07/05/22 Barclays
Ligand price target lowered to $157 from $165 at Barclays
LLY Eli Lilly
$365.17 /

+7.95 (+2.23%)

11/02/22 Wells Fargo
Eli Lilly price target raised to $365 from $305 at Wells Fargo
11/02/22 Barclays
Eli Lilly price target raised to $395 from $355 at Barclays
11/01/22 Piper Sandler
AbCellera price target lowered to $21 from $22 at Piper Sandler
10/18/22 Piper Sandler
Akouos downgraded to Neutral from Overweight at Piper Sandler
EXEL Exelixis
$16.37 /

-0.095 (-0.58%)

11/02/22 Cowen
Exelixis price target lowered to $21 from $26 at Cowen
10/31/22 EF Hutton
Exelixis initiated with a Buy at EF Hutton
10/18/22 JMP Securities
Exelixis initiated with an Outperform at JMP Securities
10/12/22 Guggenheim
Initial data for Exelixis's XB002 show encouraging safety, says Guggenheim
EXAS Exact Sciences
$38.13 /

+0.585 (+1.56%)

11/07/22 Raymond James
Exact Sciences price target lowered to $60 from $70 at Raymond James
11/07/22 BTIG
Exact Sciences price target lowered to $65 from $70 at BTIG
11/04/22 Baird
Exact Sciences price target lowered to $60 from $75 at Baird
11/04/22 Citi
Exact Sciences price target lowered to $35 from $50 at Citi
BAYRY Bayer
$13.71 /

+0.19 (+1.41%)

10/26/22 Morgan Stanley
Bayer price target raised to EUR 81 from EUR 80 at Morgan Stanley
10/25/22 Capital One
Arvinas initiated with an Overweight at Capital One
10/12/22 Redburn
Bayer upgraded to Buy from Neutral at Redburn
09/07/22 Morgan Stanley
Bayer price target lowered to EUR 80 from EUR 87 at Morgan Stanley
BD Budget Group
/

+

BMRN BioMarin
$81.28 /

-1.15 (-1.40%)

10/31/22 Oppenheimer
BioMarin upgraded to Outperform from Perform at Oppenheimer
10/26/22 Piper Sandler
Handwringing over BioMarin's Roctavian misplaced, says Piper Sandler
10/24/22 JPMorgan
BioMarin price target lowered to $112 from $140 at JPMorgan
10/13/22 RBC Capital
BioMarin price target raised to $95 from $90 at RBC Capital
BMY Bristol-Myers
$79.21 /

+0.395 (+0.50%)

11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
10/31/22 Guggenheim
2seventy Bio initiated with a Buy at Guggenheim
10/12/22 Barclays
Bristol-Myers price target lowered to $66 from $69 at Barclays
10/10/22 Guggenheim
Guggenheim downgrades Bristol-Myers ahead of 'large and pricey' Phase 3 trials
CALT Calliditas Therapeutics
$14.91 /

-0.555 (-3.59%)

06/16/22 Kepler Cheuvreux
Calliditas Therapeutics initiated with a Buy at Kepler Cheuvreux
06/02/22 Pareto
Calliditas Therapeutics initiated with a Buy at Pareto
03/15/22 Citi
Calliditas Therapeutics price target lowered to $76 from $84 at Citi
12/20/21 H.C. Wainwright
Calliditas price target raised to $62 from $52 at H.C. Wainwright
ALBO Albireo Pharma
$22.36 /

+0.74 (+3.42%)

10/24/22 Piper Sandler
Mirum's LIVMARLI PFIC data shows superiority to Albireo's Bylvay, says Piper
10/12/22 H.C. Wainwright
Albireo Pharma price target raised to $68 from $54 at H.C. Wainwright
10/12/22 Baird
Albireo Pharma price target raised to $55 from $43
10/11/22 Piper Sandler
Piper says Bylvay safety, efficacy look similar to Mirum's Livmarli
ALGS Aligos Therapeutics
/

+

08/08/22 Cantor Fitzgerald
Aligos Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
05/05/22 SVB Securities
Aligos Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
03/22/22 Piper Sandler
Aligos Therapeutics downgraded to Neutral from Overweight at Piper Sandler
01/07/22 JPMorgan
Aligos Therapeutics downgraded to Neutral from Overweight at JPMorgan
ALIM Alimera Sciences
$5.50 /

+0.23 (+4.36%)

07/28/22 H.C. Wainwright
Alimera Sciences price target raised to $9 from $8 at H.C. Wainwright
05/10/22 H.C. Wainwright
Alimera Sciences price target lowered to $8 from $10 at H.C. Wainwright
02/25/22 Alliance Global Partners
Alimera price target lowered to $11 from $14.50 at Alliance Global Partners
02/25/22 H.C. Wainwright
Alimera Sciences price target lowered to $10 from $12 at H.C. Wainwright
ALNY Alnylam
$204.94 /

-3.4 (-1.63%)

11/02/22 H.C. Wainwright
Alnylam price target lowered to $415 from $430 at H.C. Wainwright
10/24/22 JPMorgan
Alnylam price target lowered to $200 from $204 at JPMorgan
10/07/22 BMO Capital
Alnylam's Oxlumo label expansion modest positive for franchise, says BMO Capital
10/03/22 Jefferies
Alnylam price target raised to $232 from $218 at Jefferies
ALT Altimmune
$11.63 /

-0.18 (-1.52%)

09/16/22 Guggenheim
Altimmune price target lowered to $26 from $31 at Guggenheim
09/16/22 H.C. Wainwright
Altimmune selloff post Phase 1 data overdone, says H.C. Wainwright
09/14/22 Evercore ISI
Altimmune a 'reasonable buy on weakness,' says Evercore ISI
09/14/22 Piper Sandler
Piper says conviction in pemvidutide stronger after call with Altimmune team
ALXN Alexion
$182.40 /

+ (+0.00%)

ASMB Assembly Biosciences
$1.49 /

-0.04 (-2.61%)

10/24/22 Truist
Assembly Biosciences downgraded to Hold from Buy at Truist
07/21/22 H.C. Wainwright
Assembly price target lowered to $2.50 from $3.50 at H.C. Wainwright
04/01/22 Truist
Assembly Biosciences price target lowered to $12 from $15 at Truist
AXLA Axcella Health
/

+

11/02/22 Chardan
Axcella Health price target lowered to $5 from $7 at Chardan
11/02/22 H.C. Wainwright
Axcella Health price target lowered to $8 from $10 at H.C. Wainwright
09/29/22 Roth MKM
Roth reiterates $19 target on Axcella after 'encouraging' data
08/03/22 H.C. Wainwright
Axcella Health price target lowered to $8 from $14 at H.C. Wainwright
JNJ Johnson & Johnson
$173.05 /

+1.74 (+1.02%)

11/02/22 Morgan Stanley
Abiomed upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/22 Deutsche Bank
Abiomed downgraded to Hold from Buy at Deutsche Bank
11/01/22 Piper Sandler
Abiomed downgraded to Neutral from Overweight at Piper Sandler
11/01/22 Cowen
Cowen starts Legend Biotech with an Outperform on Carvykti potential
KMDA Kamada
$4.33 /

-0.05 (-1.14%)

IPSEY Ipsen
$25.84 /

+ (+0.00%)

11/03/22 UBS
Ipsen price target raised to EUR 107 from EUR 102 at UBS
11/01/22 Societe Generale
Ipsen price target raised to EUR 142 from EUR 139 at Societe Generale
10/31/22 Societe Generale
Ipsen price target raised to EUR 142 from EUR 139 at Societe Generale
10/28/22 RBC Capital
Ipsen price target raised to EUR 108 from EUR 107 at RBC Capital
IVA Inventiva
$4.23 /

-0.04 (-0.94%)

09/23/22 H.C. Wainwright
Inventiva price target lowered to $36 from $42 at H.C. Wainwright
03/09/22 Roth MKM
Roth Capital sees Inventiva as 'attractive acquisition target'
11/22/21 H.C. Wainwright
Inventiva price target raised to $42 from $40 at H.C. Wainwright
SLP Simulations Plus
$40.19 /

+2.3 (+6.07%)

10/27/22 Oppenheimer
Simulations Plus price target lowered to $65 from $75 at Oppenheimer
07/07/22 Craig-Hallum
Simulations Plus price target raised to $60 from $55 at Craig-Hallum
01/03/22 Sidoti
Simulations Plus reinstated with a Neutral at Sidoti
SMMNY Siemens Healthineers
$23.01 /

+0.25 (+1.10%)

10/18/22 Morgan Stanley
Siemens Healthineers initiated with an Overweight at Morgan Stanley
10/04/22 Barclays
Siemens Healthineers price target lowered to EUR 62 from EUR 64 at Barclays
08/25/22 UBS
Siemens Healthineers upgraded to Buy from Neutral at UBS
08/05/22 Societe Generale
Siemens Healthineers price target lowered to EUR 62.90 from EUR 64.20 at Societe Generale
SIEGY Siemens
$57.53 /

+1.04 (+1.84%)

10/14/22 Societe Generale
Siemens downgraded on 'too complacent' consensus at Societe Generale
10/14/22 Societe Generale
Siemens downgraded to Hold from Buy at Societe Generale
10/04/22 Deutsche Bank
Siemens price target lowered to EUR 145 from EUR 160 at Deutsche Bank
10/03/22 Barclays
Siemens price target lowered to EUR 90 from EUR 95 at Barclays
RARE Ultragenyx
$35.07 /

-0.255 (-0.72%)

11/03/22 Baird
Ultragenyx upgraded to Outperform from Neutral at Baird
11/03/22 Cowen
Ultragenyx price target lowered to $65 from $86 at Cowen
11/03/22 Credit Suisse
Ultragenyx price target lowered to $96 from $105 at Credit Suisse
10/13/22 Guggenheim
Ultragenyx upgraded to Buy from Neutral at Guggenheim
PKI PerkinElmer
$128.99 /

-1.49 (-1.14%)

10/06/22 Barclays
PerkinElmer price target lowered to $120 from $140 at Barclays
09/12/22 Barclays
PerkinElmer price target lowered to $140 from $149 at Barclays
08/24/22 Credit Suisse
PerkinElmer initiated with a Neutral at Credit Suisse
08/18/22 Stifel
PerkinElmer downgraded to Hold on CFO exit at Stifel
NVO Novo Nordisk
$115.09 /

+2.63 (+2.34%)

11/03/22 Credit Suisse
Novo Nordisk price target raised to DKK 860 from DKK 820 at Credit Suisse
10/14/22 Barclays
Novo Nordisk price target raised to DKK 850 from DKK 825 at Barclays
09/28/22 Oddo BHF
Novo Nordisk upgraded to Outperform from Neutral at Oddo BHF
09/14/22 Piper Sandler
Piper 'surprised' by negative Altimmune reaction after pemvidutide's 'big win'
GSK GSK
$31.95 /

-1.055 (-3.20%)

10/14/22 Barclays
GSK price target lowered to 1,450 GBp from 1,800 GBp at Barclays
10/12/22 Morgan Stanley
GSK price target raised to 1,650 GBp from 1,550 GBp at Morgan Stanley
09/29/22 Oddo BHF
GSK upgraded to Outperform from Neutral at Oddo BHF
09/22/22 Evercore ISI
Evercore upgrades Spero, quadruples target on GSK partnership
GLTO Galecto
$2.04 /

-0.09 (-4.23%)

GILD Gilead
$81.47 /

+1.09 (+1.36%)

11/01/22 Guggenheim
AnaptysBio upgraded to Buy at Guggenheim on checkpoint agonist opportunity
10/31/22 Maxim
Gilead price target raised to $92 from $84 at Maxim
10/31/22 Barclays
Gilead upgraded to Equal Weight from Underweight at Barclays
10/28/22 BMO Capital
Gilead price target raised to $72 from $63 at BMO Capital
VIR Vir Biotechnology
$27.25 /

+1.56 (+6.07%)

SRZN Surrozen
$1.97 /

-0.03 (-1.50%)

SLP Simulations Plus
$40.19 /

+2.3 (+6.07%)

RARE Ultragenyx
$35.07 /

-0.255 (-0.72%)

PKI PerkinElmer
$128.99 /

-1.49 (-1.14%)

NVO Novo Nordisk
$115.09 /

+2.63 (+2.34%)

LLY Eli Lilly
$365.17 /

+7.95 (+2.23%)

LGND Ligand
$62.79 /

+0.91 (+1.47%)

KMDA Kamada
$4.33 /

-0.05 (-1.14%)

JNJ Johnson & Johnson
$173.05 /

+1.74 (+1.02%)

GSK GSK
$31.95 /

-1.055 (-3.20%)

GLTO Galecto
$2.04 /

-0.09 (-4.23%)

GILD Gilead
$81.47 /

+1.09 (+1.36%)

EXEL Exelixis
$16.37 /

-0.095 (-0.58%)

EXAS Exact Sciences
$38.13 /

+0.585 (+1.56%)

BMY Bristol-Myers
$79.21 /

+0.395 (+0.50%)

BMRN BioMarin
$81.28 /

-1.15 (-1.40%)

BAYRY Bayer
$13.71 /

+0.19 (+1.41%)

AXLA Axcella Health
/

+

ASMB Assembly Biosciences
$1.49 /

-0.04 (-2.61%)

ALT Altimmune
$11.63 /

-0.18 (-1.52%)

ALNY Alnylam
$204.94 /

-3.4 (-1.63%)

ALIM Alimera Sciences
$5.50 /

+0.23 (+4.36%)

ALGS Aligos Therapeutics
/

+

ALBO Albireo Pharma
$22.36 /

+0.74 (+3.42%)

VIR Vir Biotechnology
$27.25 /

+1.56 (+6.07%)

SIEGY Siemens
$57.53 /

+1.04 (+1.84%)

NVO Novo Nordisk
$115.09 /

+2.63 (+2.34%)

LLY Eli Lilly
$365.17 /

+7.95 (+2.23%)

JNJ Johnson & Johnson
$173.05 /

+1.74 (+1.02%)

GSK GSK
$31.95 /

-1.055 (-3.20%)

BMY Bristol-Myers
$79.21 /

+0.395 (+0.50%)

BAYRY Bayer
$13.71 /

+0.19 (+1.41%)

VIR Vir Biotechnology
$27.25 /

+1.56 (+6.07%)

RARE Ultragenyx
$35.07 /

-0.255 (-0.72%)

PKI PerkinElmer
$128.99 /

-1.49 (-1.14%)

NVO Novo Nordisk
$115.09 /

+2.63 (+2.34%)

LLY Eli Lilly
$365.17 /

+7.95 (+2.23%)

LGND Ligand
$62.79 /

+0.91 (+1.47%)

KMDA Kamada
$4.33 /

-0.05 (-1.14%)

JNJ Johnson & Johnson
$173.05 /

+1.74 (+1.02%)

IPSEY Ipsen
$25.84 /

+ (+0.00%)

GSK GSK
$31.95 /

-1.055 (-3.20%)

GILD Gilead
$81.47 /

+1.09 (+1.36%)

EXEL Exelixis
$16.37 /

-0.095 (-0.58%)

EXAS Exact Sciences
$38.13 /

+0.585 (+1.56%)

BMY Bristol-Myers
$79.21 /

+0.395 (+0.50%)

BMRN BioMarin
$81.28 /

-1.15 (-1.40%)

BAYRY Bayer
$13.71 /

+0.19 (+1.41%)

ALT Altimmune
$11.63 /

-0.18 (-1.52%)

ALNY Alnylam
$204.94 /

-3.4 (-1.63%)

ALBO Albireo Pharma
$22.36 /

+0.74 (+3.42%)

PKI PerkinElmer
$128.99 /

-1.49 (-1.14%)

LLY Eli Lilly
$365.17 /

+7.95 (+2.23%)

JNJ Johnson & Johnson
$173.05 /

+1.74 (+1.02%)

GSK GSK
$31.95 /

-1.055 (-3.20%)

GILD Gilead
$81.47 /

+1.09 (+1.36%)

EXAS Exact Sciences
$38.13 /

+0.585 (+1.56%)

BMY Bristol-Myers
$79.21 /

+0.395 (+0.50%)

ALT Altimmune
$11.63 /

-0.18 (-1.52%)

Conference/Events
American Association for Study of Liver Diseases to hold a meeting » 23:38
11/07/22
11/07
23:38
11/07/22
23:38
WXXWY

Wuxi Biologics

$12.05 /

+0.95 (+8.56%)

, VIR

Vir Biotechnology

$27.25 /

+1.56 (+6.07%)

, SRZN

Surrozen

$1.97 /

-0.03 (-1.50%)

, LGND

Ligand

$62.79 /

+0.91 (+1.47%)

, LLY

Eli Lilly

$365.17 /

+7.95 (+2.23%)

, EXEL

Exelixis

$16.37 /

-0.095 (-0.58%)

, EXAS

Exact Sciences

$38.13 /

+0.585 (+1.56%)

, BAYRY

Bayer

$13.71 /

+0.19 (+1.41%)

, BD

Budget Group

/

+

, BMRN

BioMarin

$81.28 /

-1.15 (-1.40%)

, BMY

Bristol-Myers

$79.21 /

+0.395 (+0.50%)

, CALT

Calliditas Therapeutics

$14.91 /

-0.555 (-3.59%)

, ALBO

Albireo Pharma

$22.36 /

+0.74 (+3.42%)

, ALGS

Aligos Therapeutics

/

+

, ALIM

Alimera Sciences

$5.50 /

+0.23 (+4.36%)

, ALNY

Alnylam

$204.94 /

-3.4 (-1.63%)

, ALT

Altimmune

$11.63 /

-0.18 (-1.52%)

, ALXN

Alexion

$182.40 /

+ (+0.00%)

, ASMB

Assembly Biosciences

$1.49 /

-0.04 (-2.61%)

, AXLA

Axcella Health

/

+

, JNJ

Johnson & Johnson

$173.05 /

+1.74 (+1.02%)

, KMDA

Kamada

$4.33 /

-0.05 (-1.14%)

, IPSEY

Ipsen

$25.84 /

+ (+0.00%)

, IVA

Inventiva

$4.23 /

-0.04 (-0.94%)

, SLP

Simulations Plus

$40.19 /

+2.3 (+6.07%)

, SMMNY

Siemens Healthineers

$23.01 /

+0.25 (+1.10%)

, SIEGY

Siemens

$57.53 /

+1.04 (+1.84%)

, RARE

Ultragenyx

$35.07 /

-0.255 (-0.72%)

, PKI

PerkinElmer

$128.99 /

-1.49 (-1.14%)

, NVO

Novo Nordisk

$115.09 /

+2.63 (+2.34%)

, GSK

GSK

$31.95 /

-1.055 (-3.20%)

, GLTO

Galecto

$2.04 /

-0.09 (-4.23%)

, GILD

Gilead

$81.47 /

+1.09 (+1.36%)

AASLD 2022: The Liver…

AASLD 2022: The Liver Meeting to be held in Washington, DC on November 4-8.

ShowHide Related Items >><<
VIR Vir Biotechnology
$27.25 /

+1.56 (+6.07%)

SRZN Surrozen
$1.97 /

-0.03 (-1.50%)

SMMNY Siemens Healthineers
$23.01 /

+0.25 (+1.10%)

SIEGY Siemens
$57.53 /

+1.04 (+1.84%)

RARE Ultragenyx
$35.07 /

-0.255 (-0.72%)

PKI PerkinElmer
$128.99 /

-1.49 (-1.14%)

NVO Novo Nordisk
$115.09 /

+2.63 (+2.34%)

LLY Eli Lilly
$365.17 /

+7.95 (+2.23%)

LGND Ligand
$62.79 /

+0.91 (+1.47%)

KMDA Kamada
$4.33 /

-0.05 (-1.14%)

JNJ Johnson & Johnson
$173.05 /

+1.74 (+1.02%)

IPSEY Ipsen
$25.84 /

+ (+0.00%)

GSK GSK
$31.95 /

-1.055 (-3.20%)

GLTO Galecto
$2.04 /

-0.09 (-4.23%)

GILD Gilead
$81.47 /

+1.09 (+1.36%)

EXEL Exelixis
$16.37 /

-0.095 (-0.58%)

EXAS Exact Sciences
$38.13 /

+0.585 (+1.56%)

CALT Calliditas Therapeutics
$14.91 /

-0.555 (-3.59%)

BMY Bristol-Myers
$79.21 /

+0.395 (+0.50%)

BMRN BioMarin
$81.28 /

-1.15 (-1.40%)

BAYRY Bayer
$13.71 /

+0.19 (+1.41%)

AXLA Axcella Health
/

+

ASMB Assembly Biosciences
$1.49 /

-0.04 (-2.61%)

ALXN Alexion
$182.40 /

+ (+0.00%)

ALT Altimmune
$11.63 /

-0.18 (-1.52%)

ALNY Alnylam
$204.94 /

-3.4 (-1.63%)

ALIM Alimera Sciences
$5.50 /

+0.23 (+4.36%)

ALGS Aligos Therapeutics
/

+

ALBO Albireo Pharma
$22.36 /

+0.74 (+3.42%)

WXXWY Wuxi Biologics
$12.05 /

+0.95 (+8.56%)

04/26/22 Bernstein
Wuxi Biologics initiated with an Outperform at Bernstein
VIR Vir Biotechnology
$27.25 /

+1.56 (+6.07%)

09/14/22 SVB Securities
SVB Securities bullish on Vir Biotechnology, initiates with an Outperform
09/14/22 SVB Securities
Vir Biotechnology initiated with an Outperform at SVB Securities
09/09/22 Morgan Stanley
Vir Biotechnology initiated with an Underweight at Morgan Stanley
05/12/22 H.C. Wainwright
Vir Biotechnology price target lowered to $125 from $250 at H.C. Wainwright
SRZN Surrozen
$1.97 /

-0.03 (-1.50%)

10/17/22 JPMorgan
Surrozen initiated with a Neutral at JPMorgan
05/27/22 BofA
Surrozen downgraded to Neutral from Buy at BofA
LGND Ligand
$62.79 /

+0.91 (+1.47%)

10/25/22 H.C. Wainwright
Ligand target lowered to $135 at H.C. Wainwright after OmniAb deal approved
10/25/22 Barclays
Ligand price target lowered to $150 from $157 at Barclays
09/02/22 Roth MKM
Ligand price target lowered to $175 from $185 at Roth Capital
07/05/22 Barclays
Ligand price target lowered to $157 from $165 at Barclays
LLY Eli Lilly
$365.17 /

+7.95 (+2.23%)

11/02/22 Wells Fargo
Eli Lilly price target raised to $365 from $305 at Wells Fargo
11/02/22 Barclays
Eli Lilly price target raised to $395 from $355 at Barclays
11/01/22 Piper Sandler
AbCellera price target lowered to $21 from $22 at Piper Sandler
10/18/22 Piper Sandler
Akouos downgraded to Neutral from Overweight at Piper Sandler
EXEL Exelixis
$16.37 /

-0.095 (-0.58%)

11/02/22 Cowen
Exelixis price target lowered to $21 from $26 at Cowen
10/31/22 EF Hutton
Exelixis initiated with a Buy at EF Hutton
10/18/22 JMP Securities
Exelixis initiated with an Outperform at JMP Securities
10/12/22 Guggenheim
Initial data for Exelixis's XB002 show encouraging safety, says Guggenheim
EXAS Exact Sciences
$38.13 /

+0.585 (+1.56%)

11/07/22 Raymond James
Exact Sciences price target lowered to $60 from $70 at Raymond James
11/07/22 BTIG
Exact Sciences price target lowered to $65 from $70 at BTIG
11/04/22 Baird
Exact Sciences price target lowered to $60 from $75 at Baird
11/04/22 Citi
Exact Sciences price target lowered to $35 from $50 at Citi
BAYRY Bayer
$13.71 /

+0.19 (+1.41%)

10/26/22 Morgan Stanley
Bayer price target raised to EUR 81 from EUR 80 at Morgan Stanley
10/25/22 Capital One
Arvinas initiated with an Overweight at Capital One
10/12/22 Redburn
Bayer upgraded to Buy from Neutral at Redburn
09/07/22 Morgan Stanley
Bayer price target lowered to EUR 80 from EUR 87 at Morgan Stanley
BD Budget Group
/

+

BMRN BioMarin
$81.28 /

-1.15 (-1.40%)

10/31/22 Oppenheimer
BioMarin upgraded to Outperform from Perform at Oppenheimer
10/26/22 Piper Sandler
Handwringing over BioMarin's Roctavian misplaced, says Piper Sandler
10/24/22 JPMorgan
BioMarin price target lowered to $112 from $140 at JPMorgan
10/13/22 RBC Capital
BioMarin price target raised to $95 from $90 at RBC Capital
BMY Bristol-Myers
$79.21 /

+0.395 (+0.50%)

11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
10/31/22 Guggenheim
2seventy Bio initiated with a Buy at Guggenheim
10/12/22 Barclays
Bristol-Myers price target lowered to $66 from $69 at Barclays
10/10/22 Guggenheim
Guggenheim downgrades Bristol-Myers ahead of 'large and pricey' Phase 3 trials
CALT Calliditas Therapeutics
$14.91 /

-0.555 (-3.59%)

06/16/22 Kepler Cheuvreux
Calliditas Therapeutics initiated with a Buy at Kepler Cheuvreux
06/02/22 Pareto
Calliditas Therapeutics initiated with a Buy at Pareto
03/15/22 Citi
Calliditas Therapeutics price target lowered to $76 from $84 at Citi
12/20/21 H.C. Wainwright
Calliditas price target raised to $62 from $52 at H.C. Wainwright
ALBO Albireo Pharma
$22.36 /

+0.74 (+3.42%)

10/24/22 Piper Sandler
Mirum's LIVMARLI PFIC data shows superiority to Albireo's Bylvay, says Piper
10/12/22 H.C. Wainwright
Albireo Pharma price target raised to $68 from $54 at H.C. Wainwright
10/12/22 Baird
Albireo Pharma price target raised to $55 from $43
10/11/22 Piper Sandler
Piper says Bylvay safety, efficacy look similar to Mirum's Livmarli
ALGS Aligos Therapeutics
/

+

08/08/22 Cantor Fitzgerald
Aligos Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
05/05/22 SVB Securities
Aligos Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
03/22/22 Piper Sandler
Aligos Therapeutics downgraded to Neutral from Overweight at Piper Sandler
01/07/22 JPMorgan
Aligos Therapeutics downgraded to Neutral from Overweight at JPMorgan
ALIM Alimera Sciences
$5.50 /

+0.23 (+4.36%)

07/28/22 H.C. Wainwright
Alimera Sciences price target raised to $9 from $8 at H.C. Wainwright
05/10/22 H.C. Wainwright
Alimera Sciences price target lowered to $8 from $10 at H.C. Wainwright
02/25/22 Alliance Global Partners
Alimera price target lowered to $11 from $14.50 at Alliance Global Partners
02/25/22 H.C. Wainwright
Alimera Sciences price target lowered to $10 from $12 at H.C. Wainwright
ALNY Alnylam
$204.94 /

-3.4 (-1.63%)

11/02/22 H.C. Wainwright
Alnylam price target lowered to $415 from $430 at H.C. Wainwright
10/24/22 JPMorgan
Alnylam price target lowered to $200 from $204 at JPMorgan
10/07/22 BMO Capital
Alnylam's Oxlumo label expansion modest positive for franchise, says BMO Capital
10/03/22 Jefferies
Alnylam price target raised to $232 from $218 at Jefferies
ALT Altimmune
$11.63 /

-0.18 (-1.52%)

09/16/22 Guggenheim
Altimmune price target lowered to $26 from $31 at Guggenheim
09/16/22 H.C. Wainwright
Altimmune selloff post Phase 1 data overdone, says H.C. Wainwright
09/14/22 Evercore ISI
Altimmune a 'reasonable buy on weakness,' says Evercore ISI
09/14/22 Piper Sandler
Piper says conviction in pemvidutide stronger after call with Altimmune team
ALXN Alexion
$182.40 /

+ (+0.00%)

ASMB Assembly Biosciences
$1.49 /

-0.04 (-2.61%)

10/24/22 Truist
Assembly Biosciences downgraded to Hold from Buy at Truist
07/21/22 H.C. Wainwright
Assembly price target lowered to $2.50 from $3.50 at H.C. Wainwright
04/01/22 Truist
Assembly Biosciences price target lowered to $12 from $15 at Truist
AXLA Axcella Health
/

+

11/02/22 Chardan
Axcella Health price target lowered to $5 from $7 at Chardan
11/02/22 H.C. Wainwright
Axcella Health price target lowered to $8 from $10 at H.C. Wainwright
09/29/22 Roth MKM
Roth reiterates $19 target on Axcella after 'encouraging' data
08/03/22 H.C. Wainwright
Axcella Health price target lowered to $8 from $14 at H.C. Wainwright
JNJ Johnson & Johnson
$173.05 /

+1.74 (+1.02%)

11/02/22 Morgan Stanley
Abiomed upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/22 Deutsche Bank
Abiomed downgraded to Hold from Buy at Deutsche Bank
11/01/22 Piper Sandler
Abiomed downgraded to Neutral from Overweight at Piper Sandler
11/01/22 Cowen
Cowen starts Legend Biotech with an Outperform on Carvykti potential
KMDA Kamada
$4.33 /

-0.05 (-1.14%)

IPSEY Ipsen
$25.84 /

+ (+0.00%)

11/03/22 UBS
Ipsen price target raised to EUR 107 from EUR 102 at UBS
11/01/22 Societe Generale
Ipsen price target raised to EUR 142 from EUR 139 at Societe Generale
10/31/22 Societe Generale
Ipsen price target raised to EUR 142 from EUR 139 at Societe Generale
10/28/22 RBC Capital
Ipsen price target raised to EUR 108 from EUR 107 at RBC Capital
IVA Inventiva
$4.23 /

-0.04 (-0.94%)

09/23/22 H.C. Wainwright
Inventiva price target lowered to $36 from $42 at H.C. Wainwright
03/09/22 Roth MKM
Roth Capital sees Inventiva as 'attractive acquisition target'
11/22/21 H.C. Wainwright
Inventiva price target raised to $42 from $40 at H.C. Wainwright
SLP Simulations Plus
$40.19 /

+2.3 (+6.07%)

10/27/22 Oppenheimer
Simulations Plus price target lowered to $65 from $75 at Oppenheimer
07/07/22 Craig-Hallum
Simulations Plus price target raised to $60 from $55 at Craig-Hallum
01/03/22 Sidoti
Simulations Plus reinstated with a Neutral at Sidoti
SMMNY Siemens Healthineers
$23.01 /

+0.25 (+1.10%)

10/18/22 Morgan Stanley
Siemens Healthineers initiated with an Overweight at Morgan Stanley
10/04/22 Barclays
Siemens Healthineers price target lowered to EUR 62 from EUR 64 at Barclays
08/25/22 UBS
Siemens Healthineers upgraded to Buy from Neutral at UBS
08/05/22 Societe Generale
Siemens Healthineers price target lowered to EUR 62.90 from EUR 64.20 at Societe Generale
SIEGY Siemens
$57.53 /

+1.04 (+1.84%)

10/14/22 Societe Generale
Siemens downgraded on 'too complacent' consensus at Societe Generale
10/14/22 Societe Generale
Siemens downgraded to Hold from Buy at Societe Generale
10/04/22 Deutsche Bank
Siemens price target lowered to EUR 145 from EUR 160 at Deutsche Bank
10/03/22 Barclays
Siemens price target lowered to EUR 90 from EUR 95 at Barclays
RARE Ultragenyx
$35.07 /

-0.255 (-0.72%)

11/03/22 Baird
Ultragenyx upgraded to Outperform from Neutral at Baird
11/03/22 Cowen
Ultragenyx price target lowered to $65 from $86 at Cowen
11/03/22 Credit Suisse
Ultragenyx price target lowered to $96 from $105 at Credit Suisse
10/13/22 Guggenheim
Ultragenyx upgraded to Buy from Neutral at Guggenheim
PKI PerkinElmer
$128.99 /

-1.49 (-1.14%)

10/06/22 Barclays
PerkinElmer price target lowered to $120 from $140 at Barclays
09/12/22 Barclays
PerkinElmer price target lowered to $140 from $149 at Barclays
08/24/22 Credit Suisse
PerkinElmer initiated with a Neutral at Credit Suisse
08/18/22 Stifel
PerkinElmer downgraded to Hold on CFO exit at Stifel
NVO Novo Nordisk
$115.09 /

+2.63 (+2.34%)

11/03/22 Credit Suisse
Novo Nordisk price target raised to DKK 860 from DKK 820 at Credit Suisse
10/14/22 Barclays
Novo Nordisk price target raised to DKK 850 from DKK 825 at Barclays
09/28/22 Oddo BHF
Novo Nordisk upgraded to Outperform from Neutral at Oddo BHF
09/14/22 Piper Sandler
Piper 'surprised' by negative Altimmune reaction after pemvidutide's 'big win'
GSK GSK
$31.95 /

-1.055 (-3.20%)

10/14/22 Barclays
GSK price target lowered to 1,450 GBp from 1,800 GBp at Barclays
10/12/22 Morgan Stanley
GSK price target raised to 1,650 GBp from 1,550 GBp at Morgan Stanley
09/29/22 Oddo BHF
GSK upgraded to Outperform from Neutral at Oddo BHF
09/22/22 Evercore ISI
Evercore upgrades Spero, quadruples target on GSK partnership
GLTO Galecto
$2.04 /

-0.09 (-4.23%)

GILD Gilead
$81.47 /

+1.09 (+1.36%)

11/01/22 Guggenheim
AnaptysBio upgraded to Buy at Guggenheim on checkpoint agonist opportunity
10/31/22 Maxim
Gilead price target raised to $92 from $84 at Maxim
10/31/22 Barclays
Gilead upgraded to Equal Weight from Underweight at Barclays
10/28/22 BMO Capital
Gilead price target raised to $72 from $63 at BMO Capital
VIR Vir Biotechnology
$27.25 /

+1.56 (+6.07%)

SRZN Surrozen
$1.97 /

-0.03 (-1.50%)

SLP Simulations Plus
$40.19 /

+2.3 (+6.07%)

RARE Ultragenyx
$35.07 /

-0.255 (-0.72%)

PKI PerkinElmer
$128.99 /

-1.49 (-1.14%)

NVO Novo Nordisk
$115.09 /

+2.63 (+2.34%)

LLY Eli Lilly
$365.17 /

+7.95 (+2.23%)

LGND Ligand
$62.79 /

+0.91 (+1.47%)

KMDA Kamada
$4.33 /

-0.05 (-1.14%)

JNJ Johnson & Johnson
$173.05 /

+1.74 (+1.02%)

GSK GSK
$31.95 /

-1.055 (-3.20%)

GLTO Galecto
$2.04 /

-0.09 (-4.23%)

GILD Gilead
$81.47 /

+1.09 (+1.36%)

EXEL Exelixis
$16.37 /

-0.095 (-0.58%)

EXAS Exact Sciences
$38.13 /

+0.585 (+1.56%)

BMY Bristol-Myers
$79.21 /

+0.395 (+0.50%)

BMRN BioMarin
$81.28 /

-1.15 (-1.40%)

BAYRY Bayer
$13.71 /

+0.19 (+1.41%)

AXLA Axcella Health
/

+

ASMB Assembly Biosciences
$1.49 /

-0.04 (-2.61%)

ALT Altimmune
$11.63 /

-0.18 (-1.52%)

ALNY Alnylam
$204.94 /

-3.4 (-1.63%)

ALIM Alimera Sciences
$5.50 /

+0.23 (+4.36%)

ALGS Aligos Therapeutics
/

+

ALBO Albireo Pharma
$22.36 /

+0.74 (+3.42%)

VIR Vir Biotechnology
$27.25 /

+1.56 (+6.07%)

SIEGY Siemens
$57.53 /

+1.04 (+1.84%)

NVO Novo Nordisk
$115.09 /

+2.63 (+2.34%)

LLY Eli Lilly
$365.17 /

+7.95 (+2.23%)

JNJ Johnson & Johnson
$173.05 /

+1.74 (+1.02%)

GSK GSK
$31.95 /

-1.055 (-3.20%)

BMY Bristol-Myers
$79.21 /

+0.395 (+0.50%)

BAYRY Bayer
$13.71 /

+0.19 (+1.41%)

VIR Vir Biotechnology
$27.25 /

+1.56 (+6.07%)

RARE Ultragenyx
$35.07 /

-0.255 (-0.72%)

PKI PerkinElmer
$128.99 /

-1.49 (-1.14%)

NVO Novo Nordisk
$115.09 /

+2.63 (+2.34%)

LLY Eli Lilly
$365.17 /

+7.95 (+2.23%)

LGND Ligand
$62.79 /

+0.91 (+1.47%)

KMDA Kamada
$4.33 /

-0.05 (-1.14%)

JNJ Johnson & Johnson
$173.05 /

+1.74 (+1.02%)

IPSEY Ipsen
$25.84 /

+ (+0.00%)

GSK GSK
$31.95 /

-1.055 (-3.20%)

GILD Gilead
$81.47 /

+1.09 (+1.36%)

EXEL Exelixis
$16.37 /

-0.095 (-0.58%)

EXAS Exact Sciences
$38.13 /

+0.585 (+1.56%)

BMY Bristol-Myers
$79.21 /

+0.395 (+0.50%)

BMRN BioMarin
$81.28 /

-1.15 (-1.40%)

BAYRY Bayer
$13.71 /

+0.19 (+1.41%)

ALT Altimmune
$11.63 /

-0.18 (-1.52%)

ALNY Alnylam
$204.94 /

-3.4 (-1.63%)

ALBO Albireo Pharma
$22.36 /

+0.74 (+3.42%)

PKI PerkinElmer
$128.99 /

-1.49 (-1.14%)

LLY Eli Lilly
$365.17 /

+7.95 (+2.23%)

JNJ Johnson & Johnson
$173.05 /

+1.74 (+1.02%)

GSK GSK
$31.95 /

-1.055 (-3.20%)

GILD Gilead
$81.47 /

+1.09 (+1.36%)

EXAS Exact Sciences
$38.13 /

+0.585 (+1.56%)

BMY Bristol-Myers
$79.21 /

+0.395 (+0.50%)

ALT Altimmune
$11.63 /

-0.18 (-1.52%)

Over a quarter ago
Hot Stocks
Assembly Biosciences presents new data as AASLD meeting » 08:18
11/04/22
11/04
08:18
11/04/22
08:18
ASMB

Assembly Biosciences

$1.60 /

-0.04 (-2.44%)

, ABUS

Arbutus Biopharma

$2.55 /

+0.195 (+8.30%)

Assembly Biosciences…

Assembly Biosciences (ASMB) reported clinical and preclinical data from its virology portfolio at the American Association for the Study of Liver Diseases, The Liver Meeting. The new data are being presented at the conference as part of four poster presentations, including two late breaker presentations. In the poster entitled "ABI-4334, a novel hepatitis B core inhibitor, accelerates capsid assembly and inhibits cccDNA formation via multiple pathways," preclinical data are presented that further demonstrate and detail the core inhibitor activity of ABI-4334 against pgRNA encapsidation and covalently closed circular DNA formation. These activities were demonstrated to be due in part to the ability of 4334 to both accelerate formation of empty capsids as well as prematurely disrupt intact capsids. These data support the advancement of 4334 into Phase 1 clinical studies. A novel class of highly potent, orally bioavailable HBV and HDV entry inhibitors is highlighted in the poster entitled "Preclinical Characterization of a Novel Class of Highly Potent Small Molecule Hepatitis B and D Virus Entry Inhibitors." This class of compounds exhibit nanomolar activity in vitro to inhibit HBV and HDV infection in hepatic cells. Lead optimization for this series is in progress at Assembly Bio, with candidate nomination anticipated in 2023. In the late-breaking poster entitled "Preclinical characterization of a novel liver-focused small molecule efficiently inhibiting hepatitis B virus by activating type I interferon signaling," data is focused on a novel class of orally bioavailable interferon-alpha receptor agonists that efficiently inhibit HBV as well as other viruses. Additionally, preliminary data suggest that this class of compounds can induce long-lasting antiviral effects when cells were exposed to compounds for even brief periods of time. Clinical results from the study evaluating first-generation core inhibitor vebicorvir in combination with Arbutus Biopharma's (BUS) AB-729 in HBV are presented in the late-breaking poster entitled "Evaluation of the vebicorvir, NrtI, and AB-729 combination in virologically suppressed patients with HBeAg negative chronic hepatitis B virus infection: Interim analysis from an open label phase 2 study." Data from this clinical trial indicate that all regimens tested were generally well tolerated. No patient achieved HBsAg loss or HBsAg seroconversion during the 48-week on-treatment period.

ShowHide Related Items >><<
ASMB Assembly Biosciences
$1.60 /

-0.04 (-2.44%)

ABUS Arbutus Biopharma
$2.55 /

+0.195 (+8.30%)

ASMB Assembly Biosciences
$1.60 /

-0.04 (-2.44%)

10/24/22 Truist
Assembly Biosciences downgraded to Hold from Buy at Truist
07/21/22 H.C. Wainwright
Assembly price target lowered to $2.50 from $3.50 at H.C. Wainwright
04/01/22 Truist
Assembly Biosciences price target lowered to $12 from $15 at Truist
ABUS Arbutus Biopharma
$2.55 /

+0.195 (+8.30%)

03/14/22 H.C. Wainwright
Arbutus Biopharma price target raised to $8.50 from $8 at H.C. Wainwright
03/04/22 Chardan
Arbutus Biopharma price target raised to $6 from $5.50 at Chardan
12/29/21 Jefferies
Arbutus Biopharma assumed with a Hold at Jefferies
12/13/21 H.C. Wainwright
H.C. Wainwright sees Arbutus' $300M-plus licensing deal for AB-729 as low-risk
ASMB Assembly Biosciences
$1.60 /

-0.04 (-2.44%)

ABUS Arbutus Biopharma
$2.55 /

+0.195 (+8.30%)

ABUS Arbutus Biopharma
$2.55 /

+0.195 (+8.30%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.